RxDoctor Payments Data

Akrivi Manola, MD

Advanced Heart Failure and Transplant Cardiology · Des Moines, IANPI 1750602041

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (54.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 52.1% of the total. Reporting peaked in 2023 at $1,860 and has fallen 73.2% since, to $499 in 2025.

$3,181in general payments, 2019–2025

Across 50 payments — averaging $63.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$2K
  • Abbott$863
  • AstraZeneca$262
  • Novartis$112
  • Pfizer$111
  • Boehringer Ingelheim$95
  • plus $79 from 6 others

What the payments were for

  • Travel & lodging$1,41044%
  • Food & beverage$1,74455%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$141,349
Medicare patients
669
Services billed
2,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis51$1,278,469
EntrestoSacubitril/Valsartan550$499,483
JardianceEmpagliflozin126$125,043
FarxigaDapagliflozin Propanediol99$97,188
EliquisApixaban82$75,667
XareltoRivaroxaban16$13,608
Bumetanide254$9,488
Metoprolol Succinate333$3,583
Torsemide128$3,538
Potassium Chloride161$2,926
Eplerenone46$1,875
Amiodarone Hcl94$1,826
Spironolactone392$1,621
Atorvastatin Calcium146$1,002
Carvedilol180$823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$111$1,354,137133 claims
NovartisEntresto$112$499,483550 claims
Boehringer IngelheimJardiance$95$125,043126 claims
AstraZenecaFarxiga$262$97,18899 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Iowaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →